Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VYNE VYNE Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VYNE
Price (delayed)
$1.22
Market cap
$20.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.99
Enterprise value
-$7.81M
VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
Highlights
VYNE's debt has dropped by 65% year-on-year and by 36% since the previous quarter
The revenue is up by 43% year-on-year and by 21% since the previous quarter
VYNE's EPS is up by 18% YoY but it is down by 6% QoQ
VYNE Therapeutics's quick ratio has shrunk by 67% YoY
VYNE's equity is down by 47% year-on-year and by 15% since the previous quarter
Key stats
What are the main financial stats of VYNE
Market
Valuations
Earnings
Shares outstanding
16.66M
Market cap
$20.33M
Enterprise value
-$7.81M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
86.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-12.92
Revenue
$605,000
Gross profit
$605,000
Operating income
-$45.45M
Net income
-$42.2M
EBIT
-$42.19M
EBITDA
-$42.18M
Free cash flow
-$37.57M
Per share
Balance sheet
Liquidity
EPS
-$0.99
EPS diluted
-$0.99
Free cash flow per share
-$0.88
Book value per share
$2.9
Revenue per share
$0.01
TBVPS
$1.32
Total assets
$56.42M
Total liabilities
$12.29M
Debt
$63,000
Equity
$44.13M
Working capital
$42.62M
Debt to equity
0
Current ratio
4.47
Quick ratio
4.09
Net debt/EBITDA
0.67
Margins
Efficiency
Dividend
EBITDA margin
-6,972.2%
Gross margin
100%
Net margin
-6,974.5%
Operating margin
-7,513.1%
Return on assets
-59%
Return on equity
-71.9%
Return on invested capital
-119.7%
Return on capital employed
-95.6%
Return on sales
-6,973.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYNE stock price
How has the VYNE Therapeutics stock price performed over time
Intraday
-2.4%
1 week
-6.15%
1 month
-32.41%
1 year
-54.81%
YTD
-63.58%
QTD
-22.78%
Financial performance
How have VYNE Therapeutics's revenue and profit performed over time
Revenue
$605,000
Gross profit
$605,000
Operating income
-$45.45M
Net income
-$42.2M
Gross margin
100%
Net margin
-6,974.5%
VYNE Therapeutics's operating income has decreased by 48% YoY and by 4.2% from the previous quarter
The net income has decreased by 45% YoY and by 6% from the previous quarter
The revenue is up by 43% year-on-year and by 21% since the previous quarter
VYNE's gross profit is up by 43% YoY and by 21% QoQ
Price vs fundamentals
How does VYNE's price correlate with its fundamentals
Growth
What is VYNE Therapeutics's growth rate over time
Valuation
What is VYNE Therapeutics stock price valuation
P/E
N/A
P/B
0.42
P/S
86.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-12.92
VYNE's EPS is up by 18% YoY but it is down by 6% QoQ
VYNE's P/B is 74% below its 5-year quarterly average of 1.6 and 30% below its last 4 quarters average of 0.6
VYNE's equity is down by 47% year-on-year and by 15% since the previous quarter
VYNE's P/S is 53% below its last 4 quarters average of 182.8 but 18% above its 5-year quarterly average of 72.7
The revenue is up by 43% year-on-year and by 21% since the previous quarter
Efficiency
How efficient is VYNE Therapeutics business performance
VYNE's return on invested capital is down by 43% since the previous quarter and by 24% year-on-year
The ROE fell by 24% YoY and by 24% QoQ
The ROA has contracted by 19% from the previous quarter and by 18% YoY
VYNE's ROS is up by 12% QoQ
Dividends
What is VYNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYNE.
Financial health
How did VYNE Therapeutics financials performed over time
VYNE Therapeutics's quick ratio has shrunk by 67% YoY
The current ratio has dropped by 66% year-on-year but it rose by 2.8% since the previous quarter
VYNE's debt is 100% smaller than its equity
VYNE's debt has dropped by 65% year-on-year and by 36% since the previous quarter
VYNE's equity is down by 47% year-on-year and by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.